This inventor holds 1 USPTO granted patent. Top assignees: Monash University, Seaport Therapeutics, Inc.. Active years: 2026.
Company Filing History:
1 out of 18 
1 out of 2 Years Active: 2026
Title: Mitchell Mcinerney: Innovator in Lipid Prodrugs
Introduction
Mitchell Mcinerney is a notable inventor based in Clayton, Australia. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of lipid prodrugs. His work focuses on enhancing the bioavailability of therapeutic agents, which is crucial for effective treatment.
Latest Patents
Mitchell Mcinerney holds a patent for "Lipid prodrugs of JAK inhibitors and uses thereof." This invention provides lymphatic system-directing lipid prodrugs and pharmaceutical compositions. It also includes methods for producing these prodrugs and compositions, as well as methods for improving the bioavailability or other properties of therapeutic agents. The patent outlines methods for treating various diseases, disorders, or conditions by administering the disclosed lipid prodrugs or pharmaceutical compositions to patients in need.
Career Highlights
Throughout his career, Mitchell has worked with prominent organizations such as Seaport Therapeutics, Inc. and Monash University. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to innovative research.
Collaborations
Mitchell has collaborated with notable individuals, including Joseph Bolen and Daniel Kenneth Bonner. These partnerships have furthered his research and development efforts in the pharmaceutical industry.
Conclusion
Mitchell Mcinerney's work in lipid prodrugs represents a significant advancement in pharmaceutical innovation. His contributions are poised to improve treatment options for various medical conditions.